The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment patterns among HCPs and concordance with expert recommendations in HER2-negative early breast cancer: Analysis of an interactive online treatment decision support tool.
 
Kelly G Brandt
No Relationships to Disclose
 
Marie N. Becker
No Relationships to Disclose
 
Tanya Gupta
Consulting or Advisory Role - bioTheranostics; Gilead Sciences; Pfizer
 
Kevin Kalinsky
Employment - EQRx (I); GRAIL (I)
Stock and Other Ownership Interests - EQRx (I); GRAIL (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship - Genentech; Immunomedics
 
Laura Spring
Consulting or Advisory Role - AstraZeneca; Daiichi Pharma; G1 Therapeutics; Lilly; Novartis; Precede Bio; Seagen
Research Funding - Genentech/Roche; Gilead Sciences; Lilly; Merck (Inst)
 
Tiffany A. Traina
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Exact Sciences; G1 Therapeutics; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Merck; Pfizer; Stemline Therapeutics; Tersera
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Pfizer (Inst)
 
Denise A. Yardley
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Immunomedics (Inst); IntegraConnect (Inst); Novartis (Inst); Stemline Therapeutics (Inst)
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Biomarin (Inst); Biothera (Inst); Dana Farber Cancer Hospital (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Polyphor (Inst); Stemline Therapeutics (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); US Oncology Network (Inst)
 
Kristen M. Rosenthal
No Relationships to Disclose